Overview and Scope
Thrombophilia is a blood disorder that increases the risk of blood clotting in the veins and arteries. It can be caused by blood clotting in arteries and veins or by an inherited (genetic) or acquired disposition. It has the potential to cause a heart attack, stroke, kidney failure, and pulmonary embolism.
Sizing and Forecast
The thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing awareness, research and development in anticoagulant therapies, aging population, genetic research, increased incidence of thrombotic disorders.
The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine, emergence of novel therapies, integration of artificial intelligence, healthcare policy and regulation, increased patient education and empowerment. Major trends in the forecast period include technological advancements , expanded role of telemedicine, rising incidence rates, biopharmaceutical developments, collaborative research initiatives.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report
Segmentation & Regional Insights
The thrombophilia market covered in this report is segmented –
1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Speciality Centres, Other End Users
North America was the largest region in the thrombophilia market in 2023. The regions covered in the thrombophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp
Major Driver Impacting Market Growth
An increase in the elderly population is expected to propel the growth of the thrombophilia market going forward. The elderly population refers to those aged 65 and up, with the proportion of the dependent population determined as the total elderly and youth population expressed as a ratio of the total population. Thrombophilic risk factors are common in elderly adults and allow for the identification of a population at risk for poor clinical outcomes, hence, the rise in the elderly population will boost the market as it creates demand for thrombophilia drugs. For instance, according to the data released by America’s Health Rankings, a US-based organization that evaluates health outcomes, in 2022, more than 56 million adults aged 65 and older account for around 16.9% of the total US population. More than 73.1 million older people are expected by 2030, when the last of the baby boomer generation enters old age. Therefore, the increase in the elderly population is driving the growth of the thrombophilia market.
Key Industry Players
Major companies operating in the thrombophilia market are adopting a strategic partnership approach, aiming to create biosynthetic heparin. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in January 2022, Optimvia, LLC, a US-based biotechnology company, announced a partnership with Ginkgo Bioworks to increase the effectiveness of biosynthetic heparin synthesis. Optimvia intends to use Ginkgo’s cell and enzyme engineering systems, as well as its fermentation manufacturing capabilities, to rapidly increase the performance of its biosynthetic heparin production method. Optimvia believes that combining its unique technique with Ginkgo’s skills would result in commercially viable, cost-effective, and safe biosynthetic heparin that may completely reduce the world’s reliance on livestock-sourced heparin. Ginkgo Bioworks is a US-based company that offers a platform for cell programming.
The thrombophilia market report table of contents includes:
1. Executive Summary
2. Thrombophilia Market Characteristics
3. Thrombophilia Market Trends And Strategies
4. Thrombophilia Market – Macro Economic Scenario
5. Global Thrombophilia Market Size and Growth
.
.
.
31. Global Thrombophilia Market Competitive Benchmarking
32. Global Thrombophilia Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Thrombophilia Market
34. Thrombophilia Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report
https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
